TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Tapan M. Kadia, Preetesh Jain, Farhad Ravandi, Guillermo Garcia-Manero, Michael Andreef, Koichi Takahashi, Gautam Borthakur, Elias Jabbour, Marina Konopleva, Naval G. Daver, Courtney Dinardo, Sherry Pierce, Rashmi Kanagal-Shamanna, Keyur Patel, Zeev Estrov, Jorge Cortes, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

149 Scopus citations


BACKGROUND: Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in patients with acute myeloid leukemia (AML). METHODS: Peripheral blood or bone marrow samples from 293 patients with newly diagnosed AML were analyzed with targeted, amplicon-based, next-generation sequencing-based mutation analysis. RESULTS: TP53 mutations were identified in 53 patients (18%; 45 were missense mutations). In 13 of the 53 patients, the most common pattern of amino acid substitution was a substitution of arginine to histidine on different codons. The clinical characteristics, pattern of mutations, response to different therapies, and outcomes of patients with AML-TP53–mutated (n = 53) versus wild-type TP53 (n = 240) were compared. TP53 mutations were significantly more likely in patients who had a complex karyotype; abnormalities of chromosome 5, 7, and 17; and therapy-related AML. Patients who had TP53-mutated AML had significantly lower incidence of mutations in Fms-like tyrosine kinase 3 (FLT3), rat sarcoma (RAS), and nucleophosmin (NPM1) and higher incidence of coexisting MPL mutations compared with those who had wild type TP53. The distribution of TP53 mutations was equal for both age groups (ages <60 years vs ≥60 years). TP53-mutated AML was associated with a lower complete remission rate (41% vs 57%; P =.04), a significantly inferior complete remission duration (at 2 years: 30% vs 55%; P =.001), and overall survival (at 2 years: 9% vs 24%; P ≤.0001) irrespective of age or the type of treatment received (high-intensity vs low-intensity chemotherapy). CONCLUSIONS: The type of treatment received did not improve outcomes in younger or older patients with TP53-mutated AML. These data suggest that novel therapies are needed to improve the outcome of patients with AML who have TP53 mutations. Cancer 2016;122:3484–3491.

Original languageEnglish (US)
Pages (from-to)3484-3491
Number of pages8
Issue number22
StatePublished - Nov 15 2016
Externally publishedYes


  • acute myeloid leukemia (AML)
  • adverse prognosis
  • biomarkers of resistance
  • complex karyotype
  • tumor protein 53 (TP53)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes'. Together they form a unique fingerprint.

Cite this